A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies-Reference-Cited by-同舟云学术

A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies

Published:2022-07 Issue:7 Volume:22 Page:523-534
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Zeidan Amer M.,Cook Rachel J.^ORCID,Bordoni Rodolfo^ORCID,Berenson James R.,Edenfield William J.,Mohan Sanjay,Zhou Gongfu,Asatiani Ekaterine,Srinivas Nithya,Savona Michael R.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference49 articles.

1. A gain-of-function mutation of JAK2 in myeloproliferative disorders;Kralovics;N Engl J Med,2005

2. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet,2005

3. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis;Levine;Cancer Cell,2005

4. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia;Flex;J Exp Med,2008

5. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway;Heinrich;Biochem J,1998

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK/STAT signaling pathway inhibitors for leukemia therapeutic potential : a systematic review on in vitro literatures;2024-09-02

2. JAK/STAT as therapeutic signaling pathway in leukemia: a systematic review on in vitro inhibitors;2024-08-06

3. Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma;Oncotarget;2024-02-05

4. The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders;Journal of Clinical Medicine;2023-04-14

5. Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives;Pharmaceutics;2022-08-25